A Phase 1/1b Dose Escalation/Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors

Brief description of study

This study is designed for patients diagnosed with Advanced or Metastatic Solid Tumors.

For Part 1A, this study will assess the safety and tolerability at increasing dose levels of NGM831 monotherapy in successive cohorts of patients with advanced or metastatic solid tumors and inform the expansion dosing regimen(s) based on all available clinical data obtained from the Phase 1 study.

For Part 1B, this study will assess the safety and tolerability of NGM831 in combination with pembrolizumab and inform the combination expansion dosing regimen(s) based on all available clinical data obtained from the Phase 1 study.


Clinical Study Identifier: s21-00449
Principal Investigator: Nina Beri.
Other Investigators: Nila Theresa De La Rosa, Joshua K Sabari, Samantha VanMaanen, Jeffrey S. Weber, Salman Rafi Punekar, Elaine Shum, Jessica Wang, Kristen Spencer, Scot Niglio, Keriann M Scavone, Cosmin Adrian Tegla, Kathleen M Madden, Caitlin Elizabeth Ryan, Vamsidhar Velcheti, Douglas K Marks, Janice Mehnert, David R. Wise.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.